Email Updates

You are here

Dapivirine Ring Results

Results from two Phase III multi-country trials (ASPIRE and Ring) studying the 4-week slow-release dapivirine vaginal ring were released at the Conference on Retroviruses and Opportunistic Infection. The trials showed modest protection reducing rates of HIV acquisition by around one-third overall with greater effect in women over 21 who had higher adherence. Below, please find press releases, background information and other useful resources about the Ring and ASPIRE studies.

Press Releases


  • Click for the presentations of the ASPIRE and Ring Study results.
  • AVAC hosted a post-CROI webinar with with Jared Baeten (MTN) and Zeda Rosenberg (IPM) where they presented their results and fielded questions from webinar participants; click here.

Background Information

Materials from IPM and MTN

Peer-Reviewed Articles

Highlighted News and Blogs


Download a PDF version of the table here.

To help understand these infographics, plesae see our Advocates' Guide to Statistical Terms.